Title: Combinational effects of maxacalcitol and betamethasone butyrate propionate on imiquimod-induced psoriasis-like dermatitis in mice
Abstract: Psoriasis is a chronic inflammatory skin disease, characterized by epidermal hyper-proliferation, abnormal differentiation and inflammatory cell infiltration. The combination therapy of vitamin D3 analogue (VD3) and glucocorticoid has been widely used for the topical treatment of psoriasis because of its better efficacy compared to each monotherapy. However, their underlying mechanisms on the combinational effects have not yet been fully elucidated. Therefore, we investigated the comparative effects of a novel VD3/glucocorticoid combination product, which contains maxacalcitol (MCT) and betamethasone butyrate propionate (BBP), with MCT or BBP single product on imiquimod (IMQ)-induced psoriasis-like dermatitis in mice. Mice were treated topically with IMQ cream for 4 consecutive days, and drugs were topically administrated for 3 days from the next day of the first IMQ treatment. MCT/BBP combination product strongly ameliorated the development of IMQ-induced psoriasis-like skin lesions. Histological findings also showed that it suppressed the thickening of epidermis and inflammatory cell infiltration in dermis. Moreover, it reduced an elevation in mRNA levels of Th17 cytokines (IL-17A, IL-17F, IL-22), inflammatory cytokines (TNF-α, IL-1β) and an antimicrobial peptide (S100A7), and increased those of epidermal differentiation markers (K1, Filaggrin, Loricrin) in dorsal skin. These effects were much stronger than the single products. In conclusion, our results demonstrated the remarkable improvement effect of MCT/BBP combination product to abnormal immune reaction and epidermal dysfunction, supporting the superior clinical efficacy of combination therapy compared to monotherapy in psoriasis.
Publication Year: 2017
Publication Date: 2017-04-08
Language: en
Type: article
Indexed In: ['crossref']
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot